Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Capecitabine
Drug: Bevacizumab

First Posted Date: 2007-05-03

Last Posted Date: 2016-01-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 62

Registration Number: NCT00468585

Locations: 🇺🇸
Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States

and more 2 locations

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Phase 1

Active, not recruiting

Conditions: Leukemia

Interventions: Biological: therapeutic autologous lymphocytes
Drug: cyclophosphamide

First Posted Date: 2007-04-27

Last Posted Date: 2025-04-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 50

Registration Number: NCT00466531

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma

Phase 2

Completed

Conditions: Kidney Cancer
Melanoma (Skin)
Metastatic Cancer

Interventions: Drug: sunitinib malate

First Posted Date: 2007-04-19

Last Posted Date: 2015-12-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 8

Registration Number: NCT00462982

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Biological: filgrastim
Drug: clofarabine
Drug: dexamethasone
Drug: thiotepa
Drug: topotecan hydrochloride
Drug: vinorelbine tartrate

First Posted Date: 2007-04-19

Last Posted Date: 2013-11-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 23

Registration Number: NCT00462787

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer

Not Applicable

Completed

Conditions: Colorectal Cancer

Interventions: Biological: bevacizumab
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2007-04-19

Last Posted Date: 2016-01-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 35

Registration Number: NCT00462501

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma

Completed

Conditions: Lymphoma

Interventions: Drug: Biaxin (clarithromycin)

First Posted Date: 2007-04-17

Last Posted Date: 2014-09-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 36

Registration Number: NCT00461084

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Drug: sunitinib malate

First Posted Date: 2007-04-13

Last Posted Date: 2015-11-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT00459875

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: bortezomib
Drug: dexamethasone

First Posted Date: 2007-04-11

Last Posted Date: 2016-08-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 40

Registration Number: NCT00458822

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: bortezomib
Drug: dexamethasone
Drug: pegylated liposomal doxorubicin hydrochloride
Drug: thalidomide

First Posted Date: 2007-04-11

Last Posted Date: 2016-01-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT00458705

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment

Phase 2

Completed

Conditions: Ovarian Cancer
Teratoma
Extragonadal Germ Cell Tumor
Testicular Germ Cell Tumor

Interventions: Drug: sunitinib malate

First Posted Date: 2007-03-28

Last Posted Date: 2015-10-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT00453310

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy